World's Best Scientists 2026 revealed!
Lidia Ruiz

Lidia Ruiz

D-Index & Metrics

Immunology

D-Index
44
Citations
8438
World Ranking
4770
National Ranking
63

Lidia Ruiz publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Lidia Ruiz sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 117 publications — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Lidia Ruiz D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Lidia Ruiz sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 44 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Lidia Ruiz is affiliated with IrsiCaixa in Spain and has contributed extensively to the field of medicine, focusing primarily on infectious diseases and COVID-19-related research. Their work spans several subfields, including oncology, neurology, genetics, and pulmonary and respiratory medicine.

Their research predominantly addresses topics such as SARS-CoV-2 and COVID-19, including clinical studies, long-term effects, detection and testing, as well as biosensors and analytical detection techniques. Additional interests include vascular anomalies and treatments, alongside pancreatic and hepatic oncology research.

Recent publications by Lidia Ruiz reflect their involvement in COVID-19 clinical and diagnostic studies. Notable papers include:

  • Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial, 2020, Clinical Infectious Diseases
  • A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19, 2020, New England Journal of Medicine
  • SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity, 2021, Scientific Reports
  • Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial, 2021, The Lancet Infectious Diseases
  • Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test, 2021, Journal of Infection

They have frequently collaborated with several coauthors, including:

  • Bonaventura Clotet (9 joint publications)
  • Natàlia Casamitjana (5 joint publications)
  • Marc Corbacho-Monné (5 joint publications)
  • María Ubals (5 joint publications)
  • Andrea Alemany (5 joint publications)

Lidia Ruiz's work has been published in various journals and venues, such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • EDULEARN proceedings
  • Clinical Infectious Diseases
  • New England Journal of Medicine
  • Scientific Reports

The scientist's scholarly contributions center on advancing understanding and treatment options in infectious diseases, particularly focusing on the COVID-19 pandemic. Their interdisciplinary approach integrates clinical research with analytical detection technologies, aiming to address challenges in diagnosis and long-term patient outcomes.

Best Publications

  • Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

    Jacques Fellay;Catia Marzolini;Emma R. Meaden;David J. Back

  • Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management

    Annemarie M. J. Wensing;David A. van de Vijver;Gioacchino Angarano;Birgitta Åsjö

  • Chemokines and receptors in HIV encephalitis.

    Virginia J. Sanders;Christopher A. Pittman;Michael G. White;Guoji Wang

  • Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

    Cristina Tural;Lidia Ruiz;Christopher Holtzer;Jonathan Schapiro

  • Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.

    Rika Draenert;Sylvie Le Gall;Katja J. Pfafferott;Alasdair J. Leslie

  • Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.

    Albert Tuldra;Carmina R. Fumaz;Ma José Ferrer;Ramon Bayes

  • Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.

    Oriol Mitjà;Marc Corbacho-Monné;Maria Ubals;Cristian Tebe

  • Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe

    Jurgen Vercauteren;Annemarie M. J. Wensing;David A. M. C. van de Vijver;Jan Albert

  • Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.

    Mónica Gumá;Cecilia Cabrera;Itziar Erkizia;Margarita Bofill

  • A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.

    Oriol Mitjà;Marc Corbacho-Monné;Maria Ubals;Andrea Alemany

  • Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

    Lidia Ruiz;Javier Martinez-Picado;Joan Romeu;Roger Paredes

  • Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

    L Ruiz;E Negredo;P Domingo;R Paredes

  • Long-Lasting Remission of Cytomegalovirus Retinitis without Maintenance Therapy in Human Immunodeficiency Virus-Infected Patients

    C. Tural;J. Romeu;G. Sirera;D. Andreu

  • Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.

    Eugenia Negredo;Luís Cruz;Roger Paredes;Lidia Ruiz

  • Secretion of interferon-γ by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18

    Laila Darwich;Gemma Coma;Ruth Peña;Rocio Bellido

  • Updated European recommendations for the clinical use of HIV drug resistance testing

    A. M. Vandamme;A. Sönnerborg;M. Ait-Khaled;J. Albert

  • HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

    Lidia Ruiz;Guislaine Carcelain;Javier Martinez-Picado;Simon Frost

  • Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

    Dimitrios Paraskevis;Dimitrios Paraskevis;Oliver Pybus;Gkikas Magiorkinis;Angelos Hatzakis

  • Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

    Eugenia Negredo;José Moltó;David Burger;Pompeyo Viciana

  • Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

    Julia G Prado;Terri Wrin;Jeff Beauchaine;Lidia Ruiz

  • Virological rebound after suppression on highly active antiretroviral therapy.

    Amanda Mocroft;Lidia Ruiz;Peter Reiss;Bruno Ledergerber

  • Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

    Alessandro Cozzi-Lepri;Andrew N Phillips;Lidia Ruiz;Bonaventura Clotet

  • Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission

    Nuria Izquierdo-Useros;Julià Blanco;Itziar Erkizia;Maria Teresa Fernández-Figueras

  • The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

    David A van de Vijver;Annemarie M J Wensing;Gioacchino Angarano;Birgitta Asjö

  • Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

    Eugenia Negredo;Josep Ribalta;Roger Paredes;Raimón Ferré

  • Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).

    J C Schmit;L Ruiz;B Clotet;A Raventos

  • SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.

    Benjamin Trinité;Ferran Tarrés-Freixas;Jordi Rodon;Edwards Pradenas

  • Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

    Lidia Ruiz;Roger Paredes;Guadalupe Gómez;Joan Romeu

Frequent Co-Authors

Javier Martinez-Picado
Javier Martinez-Picado University of Vic - Central University of Catalonia
Anne-Mieke Vandamme
Anne-Mieke Vandamme Rega Institute for Medical Research
Maurizio Zazzi
Maurizio Zazzi University of Siena
Eugenia Negredo
Eugenia Negredo University of Vic - Central University of Catalonia
Kristel Van Laethem
Kristel Van Laethem Rega Institute for Medical Research
Charles A. Boucher
Charles A. Boucher Erasmus University Rotterdam
Roger Paredes
Roger Paredes University of Vic - Central University of Catalonia
Clive Loveday
Clive Loveday University College London
Andrzej Horban
Andrzej Horban Medical University of Warsaw

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, pursuing related healthcare degrees can open diverse career paths. Fields like psychiatric nursing and nurse practitioner specializations often intersect with immunological research and patient care, offering numerous opportunities.

If you're considering advancing in nursing, exploring the best pmhnp programs is a great start. These programs not only focus on psychiatric mental health but also provide strong clinical placements, essential for hands-on experience.

Affordability is a major factor when choosing a degree. Many students benefit from looking into the cheapest psych np programs, which balance cost and quality effectively. These programs can make advancing your career more accessible without compromising education standards.

Understanding the financial outlook is also important. Knowing the doctorate in nursing salary by state helps graduates plan their futures and select locations that offer the best compensation for their expertise.

For those currently practicing as a Family Nurse Practitioner, options like the fnp to acute care np bridge program provide a pathway to specialize further. This transition enhances skills applicable in acute care and immunology-related clinical settings.

Best Scientists Citing Lidia Ruiz

Trending Scientists